ストックスクリーナーアプリを入手
14.38
2.71%
0.38
アフターアワーズ：
14.01
-0.37
-2.57%
前日終値:
$14.00
開ける：
$13.9
24時間の取引高:
122.80K
Relative Volume:
4.69
時価総額：
$34.98M
収益：
$5.02M
当期純損益:
$-20.25M
株価収益率:
-59.92
EPS:
-0.24
ネットキャッシュフロー:
$-19.08M
1週間 パフォーマンス:
+3.01%
1か月 パフォーマンス:
-1.44%
6か月 パフォーマンス:
-39.15%
1年 パフォーマンス:
+3,584%
1日の値動き範囲:
$13.90
$15.40
1週間の範囲:
$13.50
$15.40
52週間の値動き範囲:
$0.35
$30.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-05-30 | 開始されました | H.C. Wainwright | Buy |
| 2018-04-10 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | 開始されました | Northland Capital | Outperform |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2015-09-04 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-24 | 開始されました | Piper Jaffray | Overweight |
| 2015-08-24 | 開始されました | Stifel | Buy |
すべてを表示
Vtv Therapeutics Inc (VTVT) 最新ニュース
vTv Therapeutics Faces License Agreement Termination - Yahoo Finance
How the (VTVT) price action is used to our Advantage - Stock Traders Daily
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
VTv Therapeutics : Termination of Material Agreement Form 8 K - Marketscreener.com
VTv Therapeutics: Q2 Earnings Snapshot - Barchart
Alzheimer's disease Market Size in the 7MM was ~USD 3,500 Million in 2022 | DelveInsight - openPR
Trading (VTVT) With Integrated Risk Controls - Stock Traders Daily
Objective long/short (VTVT) Report - Stock Traders Daily
Alzheimer’s disease Treatment Market Size in the 7MM was ~USD 3,500 Million in 2022, estimated DelveInsight - Barchart
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Views of Wall Street’s Leading Experts on Volcon Inc - SETE News
Travere Therapeutics Inc (TVTX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Valvoline Inc [VVV] Insider Activity: An Update for Investors - Knox Daily
Ventyx Biosciences Inc (VTYX) looking to reclaim success with recent performance - SETE News
What is going on with VCHA? Cancellations, member hiatus and more - MSN
Vital Energy Inc. (VTLE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Vanguard Total Corporate Bond Fund (NASDAQ:VTC) Reaches New 52-Week High at $79.92 - MarketBeat
VTYX overperforms with a 2.18 increase in share price - US Post News
VTLE’s latest rating updates from top analysts. - Knox Daily
TV’s 2023 Market Dance: Down -32.71% – Time to Invest? - The InvestChronicle
Texas Permanent School Fund Corp Sells 9,072 Shares of Veralto Co. (NYSE:VLTO) - Defense World
Learn to Evaluate (VTVT) using the Charts - Stock Traders Daily
Travere Therapeutics Inc [TVTX] Shares Rise 2.94 % on Thursday - Knox Daily
Neighbors concerned with proposed hospital in Webster Groves - KTVI Fox 2 St. Louis
When (VTVT) Moves Investors should Listen - Stock Traders Daily
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate - Yahoo Finance
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 45.9% - Defense World
VTVT (vTv Therapeutics) Operating Cash Flow per Share : $-6.50 (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Free Cash Flow : $-21.81 Mil (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Change In Receivables : $-0.20 Mil (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Cyclically Adjusted Book per Share : $-228.01 (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Short-Term Capital Lease Obligation : $0.18 Mil (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Revenue per Share : $0.24 (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Ending Cash Position : $45.53 Mil (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Net Income From Continuing Operatio - GuruFocus.com
VTVT (vTv Therapeutics) Cash from Discontinued Operating Ac - GuruFocus.com
VTVT (vTv Therapeutics) GF Value Rank : 1 (As of Aug. 15, 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Liabilities-to-Assets : 0.56 (As of Jun. 2024) - GuruFocus.com
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Where are the Opportunities in (VTVT) - Stock Traders Daily
FDA puts High Point company's type-1 diabetes clinical trial on hold - Winston-Salem Journal
Dow Edges Lower; Ventyx Biosciences Shares Plummet - Benzinga
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks - AOL
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump - Benzinga
Nasdaq Gains 1%; McDonald's Posts Downbeat Results - Benzinga
Why Is vTv Therapeutics (VTVT) Stock Down 46% Today? - InvestorPlace
FDA places vTv Therapeutics’s cadisegliatin programme on clinical hold - Yahoo Finance
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Vtv Therapeutics Inc (VTVT) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):